Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients.

Lancranjan, I; Bruns, C; Grass, P; Jaquet, P; Jervell, J; Kendall-Taylor, P; Lamberts, S W; Marbach, P; Orskov, H; Pagani, G; Sheppard, M; Simionescu, L

Lancranjan, I; Bruns, C; Grass, P; Jaquet, P; Jervell, J; Kendall-Taylor, P; Lamberts, S W; Marbach, P; Orskov, H; Pagani, G; Sheppard, M; Simionescu, L.

Affiliation

Lancranjan I; Department of Oncology, Sandoz Pharma Ltd, Basel, Switzerland.

Metabolism ; 45(8 Suppl 1): 67-71, 1996 Aug.

Article in En | MEDLINE | ID: mdl-8769387

Subject(s)

Acromegaly/drug therapy; Octreotide/administration & dosage; Acromegaly/blood; Acromegaly/pathology; Adenoma/pathology; Capsules; Double-Blind Method; Growth Hormone/blood; Humans; Insulin-Like Growth Factor I/analysis; Microspheres; Octreotide/adverse effects; Octreotide/therapeutic use; Pituitary Neoplasms/pathology; Prospective Studies

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Acromegaly / Octreotide Type of study: Clinical_trials / Observational_studies Limits: Humans Language: En Journal: Metabolism Year: 1996 Type: Article Affiliation country: Switzerland

Search on Google

XML

PubMed Links